How streamlined pathway can help solve industry challenges?
The increased complexity of drug development activities has driven up the cost for drug development. Additionally, inflation as well as drug pricing and reimbursement constraints had a negative impact on the pharma industry and their budgets.
As a result, more and more companies are seizing the opportunity to look for alternative approaches that are more efficient and can offer extra value, such as time-saving resources and process streamlining.
By utilizing SGS PACE, companies will not only prevent significant losses of time and resources caused by ongoing back-and-forth communication between multiple teams. They will also benefit from SGS PACE’s consultancy provision which includes input from CMC, preclinical, and clinical experts who can provide multidisciplinary advice during the development process.
Who can benefit from SGS PACE?
SGS PACE is designed to be a tailor-made program with the company’s objectives and goals, as well as budgets, firmly in mind. Companies that will benefit from SGS PACE include:
- Smaller biotech companies that need additional support to manage these types of programs. They want to be able to focus on the scientific and medical aspects of their research, as well as securing appropriate funding, without spending extra time and resources on pipeline management.
- Larger pharmaceutical companies that are confronted with increased pressures on timelines and budgets.
How does SGS PACE streamline the drug pathway?
SGS PACE reduces the program’s complexity and provides additional experience and expertise that may not always be readily available from within a company’s own organization. This program is pick-and-choose and can therefore be a perfect addition to the expertise and services already available internally.
The structure of the SGS PACE program enables easy knowledge-sharing between clinics and development teams, helping our clients to optimize their formulation efficiently without needing data reviews from multiple partners, and reducing time and spend in the process.
What is SGS PACE?
A tailored approach to pipelines
When it comes to project pipelines, we understand that there is no one-size-fits-all approach to planning. Each project, program, and client will have its own individual needs. As a result, a bespoke approach is essential for successful project delivery.
Objectives and goals, as well as the client’s budget, are factored into the pipeline planning. The program is also adaptable to client’s needs and budgets.
Understanding of new regulations
The arrival of more stringent regulatory requirements, such as those set out in the new EU Clinical Trial Regulation, also brings fresh challenges for many companies. For small biotech companies that do not have inhouse regulatory experts, this can be a logistical hurdle that is difficult to overcome alone. To resolve this issue, SGS can offer regulatory advice for submissions within the EU, UK, and US, covering all aspects of drug development.
Bringing the vision of your drug to life
The increased complexity of drug development activities has driven up the cost for drug development. More and more companies are seizing the opportunity to look for alternative approaches that are more efficient and can offer extra value, such as time-saving resources and process streamlining
Companies will not only prevent significant losses of time and resources caused by ongoing back-and-forth communication they benefit from SGS PACE’s consultancy provision which includes input from experts who can provide multidisciplinary advice during the development process.
The SGS PACE program enables easy knowledge-sharing between clinics and development teams, helping our clients to optimize their formulation efficiently without needing data reviews from multiple partners, and reducing time and spend in the process.
Why is SGS PACE different?
- SGS PACE can support clients from very early preclinical stages right through to commercialization.
- Both our clinical services and our formulation development experience are underpinned by our vast network of analytical services. Primarily our bioanalytical services can support early preclinical PK studies.
- By solving any analytical challenges early this can really help to drive projects forward as we set up for initiating clinical sample analysis. In addition, our armory of techniques and methodology to support drug product characterization means we are not limited to a niche service provision for specific dosage forms. These analytical services, whether supporting preclinical, clinical, or even long-term drug product stability testing activities, are an essential part of our SGS PACE provision. This means we have the ability to solve essential problems for our clients with groups that all work together under the same quality-based principles.
- Our collective expertise within SGS is considerable. Our SGS PACE program offering allows our clients to tap into that expertise and support to help them run successful projects, without the complexity of trying to coordinate all the moving parts.
A global footprint to streamline the drug pathway
We are SGS – the world’s leading testing, inspection, and certification company. As a global leader in testing, we offer over 140 years of experience, providing a broad range of services to clients around the globe. Our network of bioanalytical, formulation, clinical research, and clinical manufacturing solutions offers a wide range of integrated services and expertise across America and Europe.
By choosing SGS, you will be working with leading experts who will collaborate with you throughout every stage of your drug development pathway. You can leverage our industry-leading, fully accredited facilities featuring state-of-the-art equipment, and consult our knowledgeable specialists throughout the development process.